Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine - A review

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 12, 2011, Pages 2269-2281

  Eberlein, Uta ^a   Bröer, Jörn Hendrik ^b   Vandevoorde, Charlot ^c   Santos, Paula ^d   Bardiès, Manuel ^d   Bacher, Klaus ^c   Nosske, Dietmar ^b   Lassmann, Michael ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b BUNDESAMT FÜR STRAHLENSCHUTZ   (Germany)

^c GHENT UNIVERSITY   (Belgium)

^d Team 12   (France)

Author keywords

Biokinetics; Diagnostic radiopharmaceuticals; Dosimetry; Effective dose

Indexed keywords

ACETIC ACID C 11; BESILESOMAB; CHOLINE; CHOLINE C 11; CYSTEINE ETHYL ESTER TC 99M; DOPA; FLORBETABEN; FLUORIDE; FLUORINE 18; FLUORODEOXYGLUCOSE; GALLIUM 68; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IASODOPA; IBRITUMOMAB TIUXETAN; IODINE 123; IOFLUPANE I 123; MACROSALB I 131; MACROSALB TC 99M; MEDRONIC ACID; METHIONINE C 11; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NANOCOLL TC 99M; PENTETIC ACID; PENTETREOTIDE; PERTECHNETIC ACID TC 99M; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82; SUCCIMER; TECHNEGAS; TECHNETIUM 99M; TETROFOSMIN TC 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER DIAGNOSIS; CHOLINE UPTAKE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG UPTAKE; EUROPE; HUMAN; INFORMATION PROCESSING; INTENSITY MODULATED RADIATION THERAPY; MEDICAL DOCUMENTATION; MEDLINE; MICTURITION; NONHUMAN; NUCLEAR MEDICINE; PEDIATRICS; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; RADIODIAGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BODY BURDEN; COMPUTER SIMULATION; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; RADIATION DOSAGE; RADIOMETRY; RADIOPHARMACEUTICALS;

EID: 84856211566     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1904-z     Document Type: Review

References (113)

1. ICRP. Publication 53: Radiation dose to patients from radiopharmaceuticals. Ann ICRP. 1987;18 (1-4).
2. ICRP. Publication 80: Radiation dose to patients from radiopharmaceuticals: Addendum 2 to ICRP publication 53. Ann ICRP. 1998;28(3).
3. ICRP. Publication 106: Radiation dose to patients from radiopharmaceuticals: Addendum 3 to ICRP Publication 53. Ann ICRP. 2008;38 (1-2).
4. Lassmann M, Chiesa C, Flux G, Bardiès M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38(1):192-200.
5. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry - standardization of nomenclature. J Nucl Med. 2009;50(3):477-84.
6. 90Y- ibritumomab tiuxetan. J Nucl Med. 2009;50(4):644-52.
7. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37S-61S. (Pubitemid 29077103)
8. Snyder WS, Ford MR, Warner GG, Watson SB. MIRD Pamphlet No 11: S, absorbed dose per unit cumulated activity for selected radionuclides and organs. Reston: Society of Nuclear Medicine; 1975.
9. ICRP. Publication 103: The 2007 recommendations of the International Commission of Radiological Protection. Ann ICRP. 2007;37 (2-4).
10. ICRP. Publication 60:1990 recommendations of the International Commission on Radiological Protection. Ann ICRP. 1991;21 (1-3).
11. ICRP. Publication 26: Recommendations of the ICRP. Ann ICRP. 1971;1(3).
12. Stabin MG. Uncertainties in internal dose calculations for radiopharmaceuticals. J Nucl Med. 2008;49(5):853-60. (Pubitemid 351717553)
13. van den Hoff J, Burchert W, Wolpers HG, Meyer GJ, Hundeshagen H. A kinetic model for cardiac PET with [1-carbon-11]-acetate. J Nucl Med. 1996;37(3):521-9. (Pubitemid 26094286)
14. Bouchelouche K, Turkbey B, Choyke P, Capala J. Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep. 2010;11(3):180-90.
15. Seltzer MA, Jahan SA, Sparks R, Stout DB, Satyamurthy N, Dahlbom M, et al. Radiation dose estimates in humans for (11) C-acetate whole-body PET. J Nucl Med. 2004;45(7):1233-6. (Pubitemid 47611670)
16. Stabin MG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37(3):538-46. (Pubitemid 26094290)
17. Shields AF, Graham MM, Kozawa SM, Kozell LB, Link JM, Swenson ER, et al. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med. 1992;33(4):581-4.
18. Leggett RW, Williams LR. A proposed blood circulation model for Reference Man. Health Phys. 1995;69(2):187-201.
19. Roivainen A, Forsback S, Grönroos T, Lehikoinen P, Kähkönen M, Sutinen E, et al. Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med. 2000;27(1):25-32. (Pubitemid 30097256)
20. 11C]choline: a comparison between rat and human data. Eur J Nucl Med Mol Imaging. 2010;37(5):874-83.
21. Deloar HM, Fujiwara T, Nakamura T, Itoh M, Imai D, Miyake M, et al. Estimation of internal absorbed dose of L-[methyl-11C] methionine using whole-body positron emission tomography. Eur J Nucl Med. 1998;25(6):629-33. (Pubitemid 28297838)
22. 11C-PiB and 18F-BAY94-9172. J Nucl Med. 2009;50(2):309-15.
23. IASON. IASOcholine: [18F] fluorocholine. http://www.iason.eu/en/products/ iasocholine.html. Accessed 10 Aug. 2011.
24. De Grado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002;43(1):92-6.
25. Erratum in: J Nucl Med 2002 Apr; 43(4):509
26. Nosske D, Brix G. Dose assessment for C-11-and F-18-choline. J Nucl Med. 2009;50 Suppl 2:1851.
27. Janzen T, Tavola F, Giussani A, Cantone MC, Uusijarvi H, Mattsson S, et al. Compartmental model of 18F-choline. Proc SPIE. 2010;7626:76261E. doi:10.1117/12.844219
28. Zankl M, Petoussi-Henss N, Janzen T, Uusijärvi H, Schlattl H, Li WB, et al. New calculations for internal dosimetry of betaemitting radiopharmaceuticals. Radiat Prot Dosimetry. 2010;139(1-3):245-9.
29. IASON. SPC IASOdopa: Summary of product characteristics. http://afssaps-prd.afssaps.fr/html/par-eu/20080604-fr328-iasodopa-spc.pdf. Accessed 10 Aug. 2011.
30. ICRP. Addendum 4 to ICRP Publication 53 (interim 2002-10-15): Radiation dose to patients from radiopharmaceuticals. http://www.icrp.org/docs/P053- addendum-4-%28interim-2002-10-15%29.pdf. Accessed 11 Aug. 2010.
31. Brown WD, Oakes TR, De Jesus OT, Taylor MD, Roberts AD, Nickles RJ, et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J Nucl Med. 1998;39(11):1884-91. (Pubitemid 28518887)
32. Mejia AA, Nakamura T, Masatoshi I, Hatazawa J, Masaki M, Watanuki S. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med. 1991;32(4):699-706.
33. 18F]fluoro-2-deoxy-D-glucose in adult humans. J Nucl Med. 1991;32(4):707-12.
34. Hays MT, Segall GM. A mathematical model for the distribution of fluorodeoxyglucose in humans. J Nucl Med. 1999;40(8):1358-66. (Pubitemid 29385646)
35. Niven E, Thompson M, Nahmias C. Absorbed dose to the adult male and female brain from 18F-fluorodeoxyglucose. Health Phys. 2001;80(1):62-6. (Pubitemid 32009615)
36. Hays MT, Watson EE, Thomas SR, Stabin M. MIRD Dose Estimate Report No. 19: Radiation absorbed dose estimates from 18F-FDG. J Nucl Med. 2002;43(2):210-4. (Pubitemid 34151045)
37. 18F]fluorodeoxyglucose positron emission imaging. Nucl Med Commun. 2002;23(8):749-55. (Pubitemid 34837005)
38. Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med. 1998;25(6):565-74. (Pubitemid 28297830)
39. 18F-FDG and comparison with the dose estimates from whole body PET. Phys Med Biol. 1999;44(2):595-606.
40. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33(10):1115-22. (Pubitemid 44484467)
41. 18F-FDG PET/CT examination. Radiat Prot Dosimetry. 2010;141(1):50-5.
42. Pauleit D, Floeth F, Herzog H, Hamacher K, Tellmann L, Müller H-W, et al. Whole-body distribution and dosimetry of O-(2-[18F] fluoroethyl)-L- tyrosine. Eur J Nucl Med Mol Imaging. 2003;30(4):519-24. (Pubitemid 36559830)
43. 18F] fluoride kinetics in humans. J Nucl Med. 1978;19(12):1301-9. (Pubitemid 9098939)
44. Hawkins RA, Choi Y, Huang S-C, Hoh CK, Dahlbom M, Schiepers C, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33(5):633-42.
45. 99mTc-methylene diphosphonate. Semin Nucl Med. 2001;31(1):28-49. (Pubitemid 32060651)
46. Drugs.com. Sodium fluoride F-18 injection. http://www.drugs.com/pro/ sodium-fluoride-f-18-injection.html. Accessed 10 Aug. 2011.
47. IASON. IASOflu: neue Zulassungen in europäischen Ländern - Update. http://www.iason.eu/news/aktuelles/details/article/iasofluneue- zulassungen-in-europaeischen-laendern.html. Accessed 10 Aug. 2011.
48. IASON. IASOflu: [18F]Natriumfluorid. http://www.iason.eu/en/products/ iasoflu.html. Accessed 10 Aug. 2011.
49. Graham MM, Peterson LM, Link JM, Evans ML, Rasey JS, Koh WJ, et al. Fluorine-18-fluoromisonidazole radiation dosimetry in imaging studies. J Nucl Med. 1997;38(10):1631-6. (Pubitemid 27443967)
50. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35(1):72-9. (Pubitemid 350234154)
51. 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116(4 Suppl):1084-92.
52. 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin. 2009;48(5):201-7.
53. Drugs.com. Cardiogen-82. http://www.drugs.com/pro/cardiogen-82.html. Accessed 10 Aug. 2011.
54. Kearfott KJ. Radiation absorbed dose estimates for positron emission tomography (PET): K-38, Rb-81, Rb-82, and Cs-130. J Nucl Med. 1982;23(12):1128-32. (Pubitemid 13198465)
55. Ryan J, Harper P, Stark V, Peterson E, Lathrop K. Radiation absorbed dose estimate for Rb-82 using in vivo measurements in man (abstract). J Nucl Med. 1984;25(5):94P.
56. 82Rb. Health Phys. 2010;99(6):811-3.
57. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023-7. (Pubitemid 43733519)
58. 82Rb. J Nucl Med. 2010;51(10):1592-9.
59. 82Rb in humans under pharmacologic stress. J Nucl Med. 2011;52(3):485-91.
60. European Medicines Agency. Scintimun: besilesomab. http://www.ema.europa. eu/ema/index.jsp?curl=pages/medicines/human/medi cines/001045/human-med-001232. jsp&murl=menus/medicines/medicines jsp&mid=WC0b01ac05800 1d124. Accessed 11 Aug. 2011.
61. Becker W, Borst U, Fischbach W, Pasurka B, Schäfer R, Börner W. Kinetic data of in-vivo labeled granulocytes in humans with a murine Tc-99m-labelled monoclonal antibody. Eur J Nucl Med. 1989;15(7):361-6. (Pubitemid 19173179)
62. Becker W, Goldenberg DM, Wolf F. The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. Semin Nucl Med. 1994;24(2):142-53.
63. Buchmann I, Kull T, Glatting G, Bunjes D, Hale G, Kotzerke J, et al. A comparison of the biodistribution and biokinetics of (99m) Tcanti-CD66 mAb BW 250/183 and Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy Eur J Nucl Med Mol Imaging. 2003;30(5):667-73. (Pubitemid 36612948)
64. IBA Molecular. Scintimun Granulocyte (in German). 2009
65. Malone LA, Malone JF, Ennis JT. Kinetics of technetium 99m labelled macroaggregated albumin in humans. Br J Radiol. 1983;56(662):109-12. (Pubitemid 13138359)
66. 99mTc as sodium pertechnetate. J Nucl Med. 1976;17(1):74-7.
67. Hays MT, Berman M. Pertechnetate distribution in man after intravenous infusion: a compartmental model. J Nucl Med. 1977;18(9):898-904.
68. Smith T, Petoussi-Henss N, Zankl M. Comparison of internal radiation doses estimated by MIRD and voxel techniques for a "family" of phantoms. Eur J Nucl Med Mol Imaging. 2000;27(9):1387-98.
69. Wackers FJ, Berman DS, Maddahi J, Watson DD, Beller GA, Strauss HW, et al. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med. 1989;30(3):301-11. (Pubitemid 19077319)
70. Leide S, Diemer H, Ahlgren L. In vivo distribution and dosimetry of Tc-99m MIBI in man. In: Watson E, Stelson A, editors. Fifth International Radiopharmaceutical Dosimetry Symposium. CONF-910529. Oak Ridge, TN: Oak Ridge Associated Universities; 1992. p. 483-97.
71. Cyclopharm. Technegas. http://www.cyclopharm.com/de/technegas4. Accessed 10 Aug. 2011.
72. Burch WM, Sullivan PJ, McLaren CJ. Technegas - a new ventilation agent for lung scanning. Nucl Med Commun. 1986;7(12):865-71. (Pubitemid 17221297)
73. Kereiakles JG, Rosenstein M. Handbook of radiation doses in nuclear medicine and diagnostic X-ray. Florida: CRC Press; 1980.
74. Snyder WS, Ford MR, Warner GG MIRD Pamphlet No 5 revised: Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantoms. Reston: Society of Nuclear Medicine; 1978.
75. ICRP Publication 23: Reference Man: Anatomical, physiological and metabolic characteristics. Oxford: Pergamon Press; 1975.
76. Cristy M. Mathematical phantoms representing children of various ages for use in estimates of internal dose. Report ORNL/NUREG/TM-367. US Nuclear Regulatory Commission and Oak Ridge National Laboratory; 1980.
77. Cristy M, Eckerman KF. Specific absorbed fractions of energy at various ages from internal photon sources. ORNL/TM-8381 V1-V7. Oak Ridge National Laboratory; 1987.
78. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85(3):294-310. (Pubitemid 36999340)
79. 99mTc-P53, a new myocardial perfusion imaging agent. In: Fifth International Radiopharmaceutical Dosimetry Symposium. CONF-910529, Oak Ridge Associated Universities, Oak Ridge, TN,. 1992. p. 467-481.
80. Higley B, Smith FW, Smith T, Gemmell HG, Das Gupta P, Gvozdanovic DV, et al. Technetium-99m-1, 2-bis[bis (2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med. 1993;34(1):30-8. (Pubitemid 23014224)
81. GE Healthcare. Myoview. http://md.gehealthcare.com/shared/pdfs/pi/ Myoview.pdf. Accessed 10 Aug. 2011.
82. 201Tl-thallous chloride. J Nucl Med. 2005;46(3):502-8. (Pubitemid 43093161)
83. Krahwinkel W, Herzog H, Feinendegen LE. Pharmacokinetics of thallium-201 in normal individuals after routine myocardial scintigraphy. J Nucl Med. 1988;29(9):1582-6.
84. Johansson L, Leide-Svegborn S, Mattsson S, Nosslin B. Biokinetics of iodide in man: refinement of current ICRP dosimetry models. Cancer Biother Radiopharm. 2003;18(3):445-50. (Pubitemid 36917887)
85. 123I] FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med. 1998;25(1):24-30. (Pubitemid 28107900)
86. Erratum in: Eur J Nucl Med 1998;25(4):458
87. GE Healthcare. DaTSCAN: EPAR-Product Information. 2007; http://www.ema.europa.eu. Accessed 14 Oct. 2010.
88. Virgolini I, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med. 1998;39(11):1928-36. (Pubitemid 28518895)
89. 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2006;33(5):532-40.
90. 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31(9):1257-62. (Pubitemid 39222489)
91. 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med. 1999;40(5):762-7. (Pubitemid 29210749)
92. 111In-DOTA- Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC. Eur J Nucl Med Mol Imaging. 1999;26(8):877-86. (Pubitemid 29397000)
93. 111In DTPA-D-Phe-octreotide in man assessed by whole body scintigraphy. Acta Radiol. 1994;35(1):53-7.
94. Stabin MG, Kooij PP, Bakker WH, Inoue T, Endo K, Coveney J, et al. Radiation dosimetry for indium-111-pentetreotide. J Nucl Med. 1997;38(12):1919-22. (Pubitemid 28030923)
95. 111In-DTPA-octreotide. Eur J Nucl Med. 2001;28(12):1743-50.
96. 86Y-DOTA- Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31(10):1386-92. (Pubitemid 39361934)
97. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000;27(7):766-77. (Pubitemid 30456759)
98. Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001;39(1-2):181-94. (Pubitemid 32564871)
99. 72Ga-citrate. J Nucl Med. 1973;14(10):755-756.
100. Ruotsalainen U, Suhonen-Polvi H, Eronen E, Kinnala A, Bergman J, Haaparanta M, et al. Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med. 1996;37(2):387-93. (Pubitemid 26150921)
101. Cristy M, Eckerman KF. Specific absorbed fractions of energy at various ages from internal photon sources. I. Methods. ORNL/TM-8381/V1. Oak Ridge National Laboratory; 1987.
102. 18F-fluorodeoxyglucose. Health Phys. 2003;84(3):307-16. (Pubitemid 36206046)
103. Gelfand MJ. Dosimetry of FDG PET/CT and other molecular imaging applications in pediatric patients. Pediatr Radiol. 2009;39 Suppl 1:46-56.
104. Lim R, Fahey FH, Drubach LA, Connolly LP, Treves ST. Early experience with fluorine-18 sodium fluoride bone PET in young patients with back pain. J Pediatr Orthop. 2007;27(3):277-82. (Pubitemid 46573178)
105. Fahey FH. Dosimetry of pediatric PET/CT. J Nucl Med. 2009;50(9):1483-91.
106. Piepsz A, Hahn K, Roca I, Ciofetta G, Toth G, Gordon I, et al. A radiopharmaceuticals schedule for imaging in paediatrics. Paediatric Task Group European Association Nuclear Medicine. Eur J Nucl Med. 1990;17(3-4):127-9.
107. Evans K, Lythgoe MF, Anderson PJ, Smith T, Gordon I. Biokinetic behavior of technetium-99m-DMSA in children. J Nucl Med. 1996;37(8):1331-5. (Pubitemid 26330665)
108. Smith T, Evans K, Lythgoe MF, Anderson PJ, Gordon I. Radiation dosimetry of technetium-99m-DMSA in children. J Nucl Med. 1996;37(8):1336-42. (Pubitemid 26330666)
109. Vestergren E, Jacobson L, Mattson S, Johansson L, Bjure J, Sixt R, et al. Biokinetics and dosimetry of Tc-99m HM-PAO in children. In: Stelson A, Watson E, editors. Fifth International Radiopharmaceutical Dosimetry Symposium. CONF-910529. Oak Ridge: Oak Ridge Associated Universities; 1992. p. 444-56.
110. Stabin M, Taylor A, Conway J, Eshima D, Wooten W, Halama J. Radiation dosimetry for Tc-99m MAG 3 in adults and children. In: Stelson A, Watson E, editors. Fifth International Radiopharmaceutical Dosimetry Symposium. CONF-910529. Oak Ridge: Oak Ridge Associated Universities; 1992. p. 432-43.
111. Gelfand MJ, Thomas SR, Kereiakes JG. Absorbed radiation dose from routine imaging of the skeleton in children. Ann Radiol (Paris). 1983;26(5):421-3. (Pubitemid 13017676)
112. ICRU. Absorbed-dose specification in nuclear medicine (report 67). J ICRU. 2002;2(1).
113. ICRP. Publication 110: Adult reference computational phantoms. Ann ICRP. 2009;30(2).